/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Mainz Biomed NV

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.13 0(0%) MYNZ at 04 Dec 2025 04:39 PM Diagnostics & Research
Lowest Today 1.14
Highest Today 1.175
Today’s Open 1.175
Prev. Close 1.16
52 Week High 8.20
52 Week Low 0.92
Day’s Range: Low 1.14 High 1.175
52-Week Range: Low 0.92 High 8.20
1 day return -
1 Week return +6.48
1 month return -17.85
3 month return -29.87
6 month return -43.62
1 year return -82.83
3 year return -86.14
5 year return -
10 year return -

Institutional Holdings

Armistice Capital, LLC 6.23

Dauntless Investment Group, LLC 1.09

Journey Advisory Group, LLC 0.33

LPL Financial Corp 0.26

Steward Partners Investment Advisory, LLC 0.22

UBS Group AG 0.21

Provenance Wealth Advisors 0.03

Advisor Group Holdings, Inc. 0.02

Morgan Stanley - Brokerage Accounts 0.02

Newbridge Financial Services Group, Inc. 0.01

SBI Securities Co Ltd 0.01

Fidelity Nasdaq Composite Index 0.00

IFP Advisors, LLC 0.00

Citigroup Inc 0.00

Virtu Financial LLC 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 7.90 M

PB Ratio 3.8285

PE Ratio 0.0

Enterprise Value 10.84 M

Total Assets 13.24 M

Volume 90592

Company Financials

Annual Revenue FY23:873999 0.9M, FY22:529877 0.5M, FY21:577348 0.6M, FY20:493565 0.5M, FY19:281393 0.3M

Annual Profit FY23:411221 0.4M, FY22:182151 0.2M, FY21:177622 0.2M, FY20:123085 0.1M, FY19:-61271 -0.1M

Annual Net worth FY23:-29301062 -29.3M, FY22:-26452725 -26.5M, FY21:-12072280 -12.1M, FY20:-886177 -0.9M, FY19:-1174766 -1.2M

Quarterly Revenue Q1/2024:214761 0.2M, Q4/2023:214761 0.2M, Q3/2023:181669 0.2M, Q2/2023:248945 0.2M, Q1/2023:193281 0.2M

Quarterly Profit Q1/2024:40251 0.0M, Q4/2023:134734 0.1M, Q3/2023:87186 0.1M, Q2/2023:148798 0.1M, Q1/2023:36296 0.0M

Quarterly Net worth Q1/2024:-5183327 -5.2M, Q4/2023:-5183327 -5.2M, Q3/2023:-6299757 -6.3M, Q2/2023:-8251727 -8.3M, Q1/2023:-8188662 -8.2M

Fund house & investment objective

Company Information Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

Organisation Diagnostics & Research

Employees 19

Industry Diagnostics & Research

CEO Mr. Guido Baechler

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow